English

Elicio Therapeutics, Inc.

EDGAR

ANGN Quarterly report (10-Q) · filed 2026-08-13

35 filing records in this dataset, filed from 2014-04-14 to 2026-08-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q1 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-8.14 million USD

2023 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -8139000 USD Source

Free cash flow

-8.16 million USD

2023 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -8139000 USD Source
Capital Expenditure: 17000 USD Source

Cash and cash equivalents: 23.5 million USD 2026-06-30 Source
Exact value

23500000 USD
Long-term debt including current maturities: 10 million USD 2025-12-31 Source
Exact value

10000000 USD
Shares outstanding: 21.9 million shares 2026-06-30 Source
Exact value

21901569 shares

Reported share-count change

34.67% · 5.64 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

16262932 shares · 2025-06-30· Source
21901569 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2022-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2025-12-31
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 12.33 million

Prior period

−USD 51.9 million

2024-01-01 – 2024-12-31
Current period

−USD 39.57 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-39571000 − -51898000 = 12327000 USD

-51898000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-39571000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Elicio Therapeutics, Inc. · 2025-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Year-over-year change in Net income: 12327000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -39571000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1912493 Filing: 000160148526000027 Input fundies:NetIncome: -51898000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1913264 Filing: 000160148526000027
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 116,000

Prior period

−USD 37.07 million

2024-01-01 – 2024-12-31
Current period

−USD 36.95 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-36952000 − -37068000 = 116000 USD

-37068000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-36952000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Elicio Therapeutics, Inc. · 2025-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Year-over-year change in Operating cash flow: 116000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -36952000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1446067 Filing: 000160148526000027 Input fundies:OperatingCashFlow: -37068000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1446718 Filing: 000160148526000027
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-81.6%

Prior period

USD 87,000

2024-01-01 – 2024-12-31
Current period

USD 16,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

16000 − 87000 = -71000 USD

87000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
16000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Elicio Therapeutics, Inc. · 2025-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Year-over-year change in Capital expenditure: -71000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 16000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1448111 Filing: 000160148526000027 Input fundies:CapitalExpenditure: 87000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1448668 Filing: 000160148526000027
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 2.3 million 100% of revenue
Operating costs Derived USD 26.03 million 1,131% of revenue
Operating income −USD 23.73 million −1,031% of revenue
Tax, interest and other Derived USD 4.48 million 194% of revenue
Net income −USD 28.21 million −1,226% of revenue

Cash

Operating cash flow −USD 22.18 million −964% of revenue
Capital expenditure USD 654,000 28% of revenue
Free cash flow Derived −USD 22.83 million −992% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 2,019% of revenue.
2021 Operating loss: operating costs were 239% of revenue.
2022 Operating loss: operating costs were 1,131% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	2880000	58153000 Derived	-55273000	24834000 Derived	-80107000	-22929000 Derived	Source 2020-01-01 – 2020-12-31: 2880000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -55273000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -80107000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -22888000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 41000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	28312000	67619000 Derived	-39307000	15266000 Derived	-54573000	-53025000 Derived	Source 2021-01-01 – 2021-12-31: 28312000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -39307000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -54573000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -52643000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 382000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	2301000	26034000 Derived	-23733000	4475000 Derived	-28208000	-22833000 Derived	Source 2022-01-01 – 2022-12-31: 2301000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -23733000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -28208000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -22179000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 654000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.3M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	2880000	Revenue: 2880000 Open source
20212021-12-31	Revenue	28312000	Revenue: 28312000 Open source
20222022-12-31	Revenue	2301000	Revenue: 2301000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-91.9% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 2880000 Open source
20212021-12-31	Year over year	883.1%	Revenue: 28312000 Open source Revenue: 2880000 Open source
20222022-12-31	Year over year	-91.9%	Revenue: 2301000 Open source Revenue: 28312000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,031.4% 2022

Net margin -1,225.9% 2022

Free cash flow margin -992.3% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-1,919.2%	Operating Income: -55273000 Open source Revenue: 2880000 Open source
20212021-12-31	Operating margin	-138.8%	Operating Income: -39307000 Open source Revenue: 28312000 Open source
20222022-12-31	Operating margin	-1,031.4%	Operating Income: -23733000 Open source Revenue: 2301000 Open source
20202020-12-31	Net margin	-2,781.5%	Net Income: -80107000 Open source Revenue: 2880000 Open source
20212021-12-31	Net margin	-192.8%	Net Income: -54573000 Open source Revenue: 28312000 Open source
20222022-12-31	Net margin	-1,225.9%	Net Income: -28208000 Open source Revenue: 2301000 Open source
20202020-12-31	Free cash flow margin	-796.1%	Revenue: 2880000 Open source Operating Cash Flow: -22888000 Open source Capital Expenditure: 41000 Open source
20212021-12-31	Free cash flow margin	-187.3%	Revenue: 28312000 Open source Operating Cash Flow: -52643000 Open source Capital Expenditure: 382000 Open source
20222022-12-31	Free cash flow margin	-992.3%	Revenue: 2301000 Open source Operating Cash Flow: -22179000 Open source Capital Expenditure: 654000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -22.2M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-22888000	Operating Cash Flow: -22888000 Open source
20212021-12-31	Operating cash flow	-52643000	Operating Cash Flow: -52643000 Open source
20222022-12-31	Operating cash flow	-22179000	Operating Cash Flow: -22179000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -22.8M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-22929000	Operating Cash Flow: -22888000 Open source Capital Expenditure: 41000 Open source
20212021-12-31	Free cash flow	-53025000	Operating Cash Flow: -52643000 Open source Capital Expenditure: 382000 Open source
20222022-12-31	Free cash flow	-22833000	Operating Cash Flow: -22179000 Open source Capital Expenditure: 654000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

60.7% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	291%	Total Liabilities: 137796000 Open source Total Assets: 47347000 Open source
20212021-12-31	Liabilities / assets	15.5%	Total Liabilities: 15006000 Open source Total Assets: 96513000 Open source
20222022-12-31	Liabilities / assets	60.7%	Total Liabilities: 13749000 Open source Total Assets: 22664000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.56× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	0.39×	Current Assets: 42297000 Open source Current Liabilities: 107449000 Open source
20212021-12-31	Current assets / current liabilities	8.08×	Current Assets: 91247000 Open source Current Liabilities: 11296000 Open source
20222022-12-31	Current assets / current liabilities	1.56×	Current Assets: 10717000 Open source Current Liabilities: 6868000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 80.11 million Exact value Exact value: -80107000 USD 2020-01-01 – 2020-12-31: -80107000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Elicio Therapeutics, Inc. · 2020-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Net Income: -80107000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -80107000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angn-20211231.htm#1966543 Filing: 000160148522000022 The citation records this snapshot. The page link may show a newer release later.	−USD 22.89 million Exact value Exact value: -22888000 USD 2020-01-01 – 2020-12-31: -22888000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Elicio Therapeutics, Inc. · 2020-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Operating Cash Flow: -22888000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22888000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angn-20211231.htm#1183904 Filing: 000160148522000022 The citation records this snapshot. The page link may show a newer release later.	USD 41,000 Exact value Exact value: 41000 USD 2020-01-01 – 2020-12-31: 41000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Elicio Therapeutics, Inc. · 2020-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Capital Expenditure: 41000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 41000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angn-20211231.htm#1186566 Filing: 000160148522000022 The citation records this snapshot. The page link may show a newer release later.	−USD 22.93 million Calculation and evidence -22888000 − 41000 USD Exact free cash flow: -22929000 USD 2020-01-01 – 2020-12-31: -22888000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 41000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Elicio Therapeutics, Inc. · 2020-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Free cash flow: -22929000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22888000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angn-20211231.htm#1183904 Filing: 000160148522000022 Input fundies:CapitalExpenditure: 41000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148522000022/angn-20211231.htm#1186566 Filing: 000160148522000022 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 54.57 million Exact value Exact value: -54573000 USD 2021-01-01 – 2021-12-31: -54573000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Elicio Therapeutics, Inc. · 2021-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Net Income: -54573000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54573000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000011/angn-20221231.htm#1223414 Filing: 000160148523000011 The citation records this snapshot. The page link may show a newer release later.	−USD 52.64 million Exact value Exact value: -52643000 USD 2021-01-01 – 2021-12-31: -52643000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Elicio Therapeutics, Inc. · 2021-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Operating Cash Flow: -52643000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -52643000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000011/angn-20221231.htm#728228 Filing: 000160148523000011 The citation records this snapshot. The page link may show a newer release later.	USD 382,000 Exact value Exact value: 382000 USD 2021-01-01 – 2021-12-31: 382000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Elicio Therapeutics, Inc. · 2021-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Capital Expenditure: 382000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 382000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000011/angn-20221231.htm#730250 Filing: 000160148523000011 The citation records this snapshot. The page link may show a newer release later.	−USD 53.03 million Calculation and evidence -52643000 − 382000 USD Exact free cash flow: -53025000 USD 2021-01-01 – 2021-12-31: -52643000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 382000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Elicio Therapeutics, Inc. · 2021-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Free cash flow: -53025000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52643000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000011/angn-20221231.htm#728228 Filing: 000160148523000011 Input fundies:CapitalExpenditure: 382000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000011/angn-20221231.htm#730250 Filing: 000160148523000011 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 28.21 million Exact value Exact value: -28208000 USD 2022-01-01 – 2022-12-31: -28208000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Elicio Therapeutics, Inc. · 2022-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Net Income: -28208000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28208000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/angn-20231231.htm#1691560 Filing: 000160148524000023 The citation records this snapshot. The page link may show a newer release later.	−USD 22.18 million Exact value Exact value: -22179000 USD 2022-01-01 – 2022-12-31: -22179000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Elicio Therapeutics, Inc. · 2022-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Operating Cash Flow: -22179000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22179000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/angn-20231231.htm#1277330 Filing: 000160148524000023 The citation records this snapshot. The page link may show a newer release later.	USD 654,000 Exact value Exact value: 654000 USD 2022-01-01 – 2022-12-31: 654000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Elicio Therapeutics, Inc. · 2022-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Capital Expenditure: 654000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 654000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/angn-20231231.htm#1279209 Filing: 000160148524000023 The citation records this snapshot. The page link may show a newer release later.	−USD 22.83 million Calculation and evidence -22179000 − 654000 USD Exact free cash flow: -22833000 USD 2022-01-01 – 2022-12-31: -22179000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 654000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Elicio Therapeutics, Inc. · 2022-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Free cash flow: -22833000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22179000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/angn-20231231.htm#1277330 Filing: 000160148524000023 Input fundies:CapitalExpenditure: 654000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000023/angn-20231231.htm#1279209 Filing: 000160148524000023 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 35.2 million Exact value Exact value: -35195000 USD 2023-01-01 – 2023-12-31: -35195000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Elicio Therapeutics, Inc. · 2023-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Net Income: -35195000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35195000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm#1832587 Filing: 000160148525000049 The citation records this snapshot. The page link may show a newer release later.	−USD 32.69 million Exact value Exact value: -32694000 USD 2023-01-01 – 2023-12-31: -32694000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Elicio Therapeutics, Inc. · 2023-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Operating Cash Flow: -32694000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32694000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm#1402179 Filing: 000160148525000049 The citation records this snapshot. The page link may show a newer release later.	USD 66,000 Exact value Exact value: 66000 USD 2023-01-01 – 2023-12-31: 66000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Elicio Therapeutics, Inc. · 2023-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Capital Expenditure: 66000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 66000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm#1404057 Filing: 000160148525000049 The citation records this snapshot. The page link may show a newer release later.	−USD 32.76 million Calculation and evidence -32694000 − 66000 USD Exact free cash flow: -32760000 USD 2023-01-01 – 2023-12-31: -32694000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 66000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Elicio Therapeutics, Inc. · 2023-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Free cash flow: -32760000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32694000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm#1402179 Filing: 000160148525000049 Input fundies:CapitalExpenditure: 66000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm#1404057 Filing: 000160148525000049 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 51.9 million Exact value Exact value: -51898000 USD 2024-01-01 – 2024-12-31: -51898000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Elicio Therapeutics, Inc. · 2024-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Net Income: -51898000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51898000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1913264 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.	−USD 37.07 million Exact value Exact value: -37068000 USD 2024-01-01 – 2024-12-31: -37068000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Elicio Therapeutics, Inc. · 2024-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Operating Cash Flow: -37068000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37068000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1446718 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.	USD 87,000 Exact value Exact value: 87000 USD 2024-01-01 – 2024-12-31: 87000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Elicio Therapeutics, Inc. · 2024-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Capital Expenditure: 87000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 87000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1448668 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.	−USD 37.16 million Calculation and evidence -37068000 − 87000 USD Exact free cash flow: -37155000 USD 2024-01-01 – 2024-12-31: -37068000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 87000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Elicio Therapeutics, Inc. · 2024-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Free cash flow: -37155000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37068000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1446718 Filing: 000160148526000027 Input fundies:CapitalExpenditure: 87000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1448668 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 39.57 million Exact value Exact value: -39571000 USD 2025-01-01 – 2025-12-31: -39571000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Elicio Therapeutics, Inc. · 2025-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Net Income: -39571000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39571000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1912493 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.	−USD 36.95 million Exact value Exact value: -36952000 USD 2025-01-01 – 2025-12-31: -36952000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Elicio Therapeutics, Inc. · 2025-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Operating Cash Flow: -36952000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36952000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1446067 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.	USD 16,000 Exact value Exact value: 16000 USD 2025-01-01 – 2025-12-31: 16000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Elicio Therapeutics, Inc. · 2025-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Capital Expenditure: 16000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1448111 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.	−USD 36.97 million Calculation and evidence -36952000 − 16000 USD Exact free cash flow: -36968000 USD 2025-01-01 – 2025-12-31: -36952000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 16000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Elicio Therapeutics, Inc. · 2025-12-31 Elicio Therapeutics, Inc. (edgar:1601485) Free cash flow: -36968000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:03:31Z Snapshot: 6cc48d006bb792b2b4df68aab7674260f43c0a29a13741765a43069aa0e45eda Dimensions: Consolidated View: https://fundies.io/companies/edgar/1601485?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36952000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1446067 Filing: 000160148526000027 Input fundies:CapitalExpenditure: 16000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm#1448111 Filing: 000160148526000027 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

35 filings · 1,847 latest values · 1,847 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001601485, 1601485, ANGN, ELTX, edgar:1601485

Also known as ANGION BIOMEDICA CORP, Angion Biomedica Corp., ELICIO THERAPEUTICS, INC., Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation